MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

被引：0

作者：

Neil Portman

Heloisa H. Milioli

Sarah Alexandrou

Rhiannon Coulson

Aliza Yong

Kristine J. Fernandez

Kee Ming Chia

Ensar Halilovic

Davendra Segara

Andrew Parker

Sue Haupt

Ygal Haupt

Wayne D. Tilley

Alex Swarbrick

C. Elizabeth Caldon

Elgene Lim

机构：

[1] Garvan Institute of Medical Research,St. Vincent’s Clinical School, Faculty of Medicine

[2] University of New South Wales Sydney,Tumor Suppression Laboratory

[3] Peter MacCallum Cancer Centre,Sir Peter MacCallum Department of Oncology

[4] The University of Melbourne,Adelaide Medical School

[5] Novartis Institutes of Biomedical Research,undefined

[6] The University of Adelaide,undefined

来源：

Breast Cancer Research | / 22卷

关键词：

Breast cancer; MDM2; Oestrogen receptor; CDK4/6 inhibitor; p53;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Lim, Elgene
Milioli, Heloisa H.
Alexandrou, Sarah
Coulson, Rhiannon
Yong, Aliza
Fernandez, Kristine J.
Chia, KeeMing
Halilovic, Ensar
Segara, Davendra
Parker, Andrew
Haupt, Sue
Haupt, Ygal
Tilley, Wayne D.
Swarbrick, Alex
Caldon, Elizabeth C.
Portman, Neil
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 110 - 110
[2] MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
Portman, Neil
Milioli, Heloisa H.
Alexandrou, Sarah
Coulson, Rhiannon
Yong, Aliza
Fernandez, Kristine J.
Chia, Kee Ming
Halilovic, Ensar
Segara, Davendra
Parker, Andrew
Haupt, Sue
Haupt, Ygal
Tilley, Wayne D.
Swarbrick, Alex
Caldon, C. Elizabeth
Lim, Elgene
BREAST CANCER RESEARCH, 2020, 22 (01)
[3] Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer
Portman, Neil
Milioli, Heloisa
Alexandrou, Sarah
Coulson, Rhiannon
Yong, Aliza
Fernandez, Kristine
Chia, KeeMing
Halilovic, Ensar
Segara, Davendra
Parker, Andrew
Haupt, Sue
Haupt, Ygal
Tilley, Wayne
Swarbrick, Alex
Caldon, Liz
Lim, Elgene
CANCER RESEARCH, 2021, 81 (04)
[4] PALBOCICLIB: CDK4/6 INHIBITION IN THE TREATMENT OF ER-POSITIVE BREAST CANCER
Owsley, J.
Jimeno, A.
Diamond, J. R.
DRUGS OF TODAY, 2016, 52 (02) : 119 - 129
[5] Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer
Lee, Nathan V.
Yuan, Jing
Eisele, Koleen
Cao, Joan Q.
Painter, Cory L.
Chionis, John
Liu, Chaoting
Shields, David J.
Kan, Julie L. C.
Arndt, Kim
VanArsdale, Todd
CANCER RESEARCH, 2014, 74 (19)
[6] Investigating the effect of CDK4/6 and MDM2 inhibition on melanoma
Slesur, Lauren
Vilgelm, Anna
Al-Rohil, Rami
Richmond, Ann
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[7] Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Portman, Neil
Alexandrou, Sarah
Carson, Emma
Wang, Shudong
Lim, Elgene
Caldon, C. Elizabeth
ENDOCRINE-RELATED CANCER, 2019, 26 (01) : R15 - R30
[8] MDM2 antagonism overcomes resistance to CDK4/6 inhibition in melanoma
Vilgelm, Anna E.
Saleh, Nabil
Riemenschneider, Kelsie
Slesur, Lauren
Chen, Sheau-Chian
Ayers, Gregory D.
Kauffman, Rondi M.
Kelley, Mark C.
Johnson, Douglas B.
Richmond, Ann
CANCER RESEARCH, 2018, 78 (13)
[9] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
Kharenko, Olesya A.
Patel, Reena G.
Calosing, Cyrus
van der Horst, Edward H.
CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
[10] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
Olesya A. Kharenko
Reena G. Patel
Cyrus Calosing
Edward H. van der Horst
Cancer Gene Therapy, 2022, 29 : 859 - 869

← 1 2 3 4 5 →